Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Stock Has Consensus Price Target of $23.36

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) has received an average rating of “Moderate Buy” from the seventeen ratings firms that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, fourteen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $23.36.

A number of research firms have recently weighed in on CMPS. Compass Point set a $25.00 price target on shares of Compass Pathways in a research note on Tuesday, July 7th. BTIG Research lifted their price objective on Compass Pathways from $14.00 to $25.00 and gave the company a “buy” rating in a research report on Tuesday, July 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Compass Pathways in a research note on Friday, July 17th. HC Wainwright dropped their target price on Compass Pathways from $70.00 to $65.00 and set a “buy” rating on the stock in a research report on Friday, August 7th. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of Compass Pathways in a research report on Wednesday, September 9th.

Hedge Funds Weigh In On Compass Pathways

Hedge funds have recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC boosted its holdings in Compass Pathways by 67.7% in the first quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company’s stock worth $26,000 after purchasing an additional 1,920 shares in the last quarter. Parallel Advisors LLC boosted its stake in shares of Compass Pathways by 8,450.6% during the 1st quarter. Parallel Advisors LLC now owns 7,268 shares of the company’s stock worth $40,000 after acquiring an additional 7,183 shares in the last quarter. North Star Investment Management Corp. boosted its stake in shares of Compass Pathways by 1,354.0% during the 1st quarter. North Star Investment Management Corp. now owns 7,517 shares of the company’s stock worth $42,000 after acquiring an additional 7,000 shares in the last quarter. Ancora Advisors LLC acquired a new position in shares of Compass Pathways during the 2nd quarter valued at about $43,000. Finally, Caitong International Asset Management Co. Ltd bought a new position in shares of Compass Pathways in the 4th quarter valued at approximately $47,000. Institutional investors and hedge funds own 46.19% of the company’s stock.

Compass Pathways Stock Performance

Shares of Compass Pathways stock opened at $11.90 on Thursday. Compass Pathways has a 12 month low of $4.88 and a 12 month high of $15.87. The stock has a market cap of $1.65 billion, a PE ratio of -2.58 and a beta of 2.55. The company has a quick ratio of 1.30, a current ratio of 1.30 and a debt-to-equity ratio of 0.60. The business has a fifty day simple moving average of $13.40 and a 200-day simple moving average of $11.25.

Compass Pathways (NASDAQ:CMPS) last issued its earnings results on Wednesday, August 5th. The company reported ($1.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($1.49). On average, sell-side analysts anticipate that Compass Pathways will post -1.26 EPS for the current fiscal year.

About Compass Pathways

Compass Pathways plc is a biotechnology company developing psychedelic treatments for mental health conditions. The company’s lead investigational product is COMP360, a proprietary formulation of synthetic psilocybin administered with psychological support in a controlled clinical setting.

Compass Pathways has focused primarily on treatment-resistant depression, a condition in which patients do not achieve adequate relief from standard therapies. Its research has also explored the potential use of COMP360 in other serious mental health disorders.